Complex Civil Litigation Law Firm

If you purchased or acquired securities in EOS Energy between November 5, 2025 and February 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Eos Energy Enterprises, Inc. (“Eos Energy” or the “Company”) (NASDAQ: EOSE) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company was unable to achieve the ramp in production and capacity utilization required to achieve its previously set guidance; (2) the Company’s battery line downtime was running well above industry norms, the design intent of the line, and internal forecasts; (3) the Company was experiencing delays in the ability for its automated bipolar production to hit quality targets; (4) the Company’s inadequate systems and processes prevented it from ensuring reasonably accurate guidance and that its public disclosures were timely, accurate, and complete; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Lead Plaintiff Deadline: May 5, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. (“Nektar” or the “Company”) (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial’s results; (3) accordingly, the REZOLVE-AA trial’s overall integrity and prospects were overstated; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Lead Plaintiff Deadline: May 5, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose true state of Boston Scientific’s U.S. EP segment; notably, that management was aware that the segment’s growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. Due to Defendants’ statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific’s net income miss and underwhelming guidance for the first half of fiscal 2026. Lead Plaintiff Deadline: May 4, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

If you purchased or acquired securities in Apollo between May 10, 2021 and February 21, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Apollo Global Management, Inc. (“Apollo” or the “Company”) (NYSE: APO) and reminds investors of the May 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants Rowan and Black, among other leadership figures at Apollo Global, frequently communicated with Jeffrey Epstein in the 2010s regarding Apollo Global’s business; (2) as a result, Apollo Global’s assertion that the Company had never done business with Jeffrey Epstein was untrue; (3) because of the entanglement between Apollo Global’s leaders and Jeffrey Epstein, the harm to Apollo Global’s reputation was more than a mere possibility; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. Lead Plaintiff Deadline: May 1, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.